Pretreatment blood pressure reliably predicts progression of chronic nephropathies
Pretreatment blood pressure reliably predicts progression of chronic nephropathies. Random, nontimed blood pressure (BP) measurements in the outpatient clinic may fail to provide reliable information on actual daily BP control in renal patients on chronic antihypertensive therapy. In a cohort of 163...
Gespeichert in:
Veröffentlicht in: | Kidney international 2000-11, Vol.58 (5), p.2093-2101 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 2101 |
---|---|
container_issue | 5 |
container_start_page | 2093 |
container_title | Kidney international |
container_volume | 58 |
creator | Ruggenenti, Piero Perna, Annalisa Lesti, Maria Pisoni, Roberto Mosconi, Lidia Arnoldi, Federica Ciocca, Ilaria Gaspari, Flavio Remuzzi, Giuseppe |
description | Pretreatment blood pressure reliably predicts progression of chronic nephropathies.
Random, nontimed blood pressure (BP) measurements in the outpatient clinic may fail to provide reliable information on actual daily BP control in renal patients on chronic antihypertensive therapy.
In a cohort of 163 patients with proteinuric chronic nephropathies followed prospectively with repeated BP and glomerular filtration rate (GFR) measurements, we compared baseline and follow-up pretreatment, morning (“trough,” measured by standard procedures, and “0 minutes,” measured by an automatic device) and post-treatment (120 minutes) measurements, with BP monitored up to 600 minutes after treatment administration. We then evaluated which BP value most reliably predicted GFR decline (δGFR) and progression to end-stage renal failure (ESRF) over a median (interquartile range) follow-up of 20 (9 to 25) months.
GFR decline was more reliably predicted by systolic as compared with diastolic BP and by pretreatment as compared to post-treatment BP, regardless of the timing and method of measurement, respectively. In particular, at the 120-minute baseline and follow-up measurements, systolic BP had no predictive value in patients with less severe renal insufficiency and baseline diastolic BP, regardless of the level of renal dysfunction. The BP predictive value was remarkably higher in ramipril than in conventionally treated patients. All follow-up—but no baseline—measurements reliably predicted the risk of ESRF in the entire study group.
In patients with progressive chronic nephropathies, systolic BP and pretreatment morning BP measurements are the most reliable predictors of disease outcome and may serve to guide antihypertensive therapy in routine clinical activities and in prospective controlled trials, particularly in patients on angiotensin-converting enzyme inhibitor therapy. Reliability and relevance of single measurements taken at different times after treatment administration are questionable. |
doi_str_mv | 10.1111/j.1523-1755.2000.00382.x |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_210104021</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0085253815473181</els_id><sourcerecordid>980035161</sourcerecordid><originalsourceid>FETCH-LOGICAL-c421t-a8f11e1f783d89da550f0456636f594167204c45eeb377497a6cccc6b080680c3</originalsourceid><addsrcrecordid>eNqFkE1PwzAMQCMEEmPwHyo4tzht06ZHmPiSJoEQnKM0dVmqrilJhrZ_T8qmXfElVvxsJ4-QiEJCQ9x2CWVpFtOSsSQFgAQg42myPSGzY-GUzAA4i1OW8XNy4VwXQF5lMCPvbxa9RenXOPio7o1potGicxuLkcVey7rfTTeNVt6FxHxNVW2GyLSRWlkzaBUNOIZslH6l0V2Ss1b2Dq8O55x8Pj58LJ7j5evTy-JuGas8pT6WvKUUaVvyrOFVIxmDFnJWFFnRsiqnRZlCrnKGWGdlmVelLFSIogYOBQeVzcn1fm541PcGnRed2dghrBQpBQo5pDRAfA8pa5yz2IrR6rW0O0FBTAJFJyZPYvIkJoHiT6DYhtabw3zplOxbKwel3bG_rCjNWaDu9xSGr_5otMIpjYMKwiwqLxqj_1_1CxCThrc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>210104021</pqid></control><display><type>article</type><title>Pretreatment blood pressure reliably predicts progression of chronic nephropathies</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>ProQuest Central UK/Ireland</source><source>Alma/SFX Local Collection</source><creator>Ruggenenti, Piero ; Perna, Annalisa ; Lesti, Maria ; Pisoni, Roberto ; Mosconi, Lidia ; Arnoldi, Federica ; Ciocca, Ilaria ; Gaspari, Flavio ; Remuzzi, Giuseppe</creator><creatorcontrib>Ruggenenti, Piero ; Perna, Annalisa ; Lesti, Maria ; Pisoni, Roberto ; Mosconi, Lidia ; Arnoldi, Federica ; Ciocca, Ilaria ; Gaspari, Flavio ; Remuzzi, Giuseppe</creatorcontrib><description>Pretreatment blood pressure reliably predicts progression of chronic nephropathies.
Random, nontimed blood pressure (BP) measurements in the outpatient clinic may fail to provide reliable information on actual daily BP control in renal patients on chronic antihypertensive therapy.
In a cohort of 163 patients with proteinuric chronic nephropathies followed prospectively with repeated BP and glomerular filtration rate (GFR) measurements, we compared baseline and follow-up pretreatment, morning (“trough,” measured by standard procedures, and “0 minutes,” measured by an automatic device) and post-treatment (120 minutes) measurements, with BP monitored up to 600 minutes after treatment administration. We then evaluated which BP value most reliably predicted GFR decline (δGFR) and progression to end-stage renal failure (ESRF) over a median (interquartile range) follow-up of 20 (9 to 25) months.
GFR decline was more reliably predicted by systolic as compared with diastolic BP and by pretreatment as compared to post-treatment BP, regardless of the timing and method of measurement, respectively. In particular, at the 120-minute baseline and follow-up measurements, systolic BP had no predictive value in patients with less severe renal insufficiency and baseline diastolic BP, regardless of the level of renal dysfunction. The BP predictive value was remarkably higher in ramipril than in conventionally treated patients. All follow-up—but no baseline—measurements reliably predicted the risk of ESRF in the entire study group.
In patients with progressive chronic nephropathies, systolic BP and pretreatment morning BP measurements are the most reliable predictors of disease outcome and may serve to guide antihypertensive therapy in routine clinical activities and in prospective controlled trials, particularly in patients on angiotensin-converting enzyme inhibitor therapy. Reliability and relevance of single measurements taken at different times after treatment administration are questionable.</description><identifier>ISSN: 0085-2538</identifier><identifier>EISSN: 1523-1755</identifier><identifier>DOI: 10.1111/j.1523-1755.2000.00382.x</identifier><identifier>CODEN: KDYIA5</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>ACE inhibition ; Antihypertensive agents ; antihypertensive therapy ; Biological and medical sciences ; Cardiovascular system ; diastolic blood pressure ; end-stage renal failure ; glomerular filtration rate ; Medical sciences ; Pharmacology. Drug treatments ; systolic blood pressure</subject><ispartof>Kidney international, 2000-11, Vol.58 (5), p.2093-2101</ispartof><rights>2000 International Society of Nephrology</rights><rights>2001 INIST-CNRS</rights><rights>Copyright Nature Publishing Group Nov 2000</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c421t-a8f11e1f783d89da550f0456636f594167204c45eeb377497a6cccc6b080680c3</citedby><cites>FETCH-LOGICAL-c421t-a8f11e1f783d89da550f0456636f594167204c45eeb377497a6cccc6b080680c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/210104021?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,777,781,27905,27906,64364,64368,72218</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=791145$$DView record in Pascal Francis$$Hfree_for_read</backlink></links><search><creatorcontrib>Ruggenenti, Piero</creatorcontrib><creatorcontrib>Perna, Annalisa</creatorcontrib><creatorcontrib>Lesti, Maria</creatorcontrib><creatorcontrib>Pisoni, Roberto</creatorcontrib><creatorcontrib>Mosconi, Lidia</creatorcontrib><creatorcontrib>Arnoldi, Federica</creatorcontrib><creatorcontrib>Ciocca, Ilaria</creatorcontrib><creatorcontrib>Gaspari, Flavio</creatorcontrib><creatorcontrib>Remuzzi, Giuseppe</creatorcontrib><title>Pretreatment blood pressure reliably predicts progression of chronic nephropathies</title><title>Kidney international</title><description>Pretreatment blood pressure reliably predicts progression of chronic nephropathies.
Random, nontimed blood pressure (BP) measurements in the outpatient clinic may fail to provide reliable information on actual daily BP control in renal patients on chronic antihypertensive therapy.
In a cohort of 163 patients with proteinuric chronic nephropathies followed prospectively with repeated BP and glomerular filtration rate (GFR) measurements, we compared baseline and follow-up pretreatment, morning (“trough,” measured by standard procedures, and “0 minutes,” measured by an automatic device) and post-treatment (120 minutes) measurements, with BP monitored up to 600 minutes after treatment administration. We then evaluated which BP value most reliably predicted GFR decline (δGFR) and progression to end-stage renal failure (ESRF) over a median (interquartile range) follow-up of 20 (9 to 25) months.
GFR decline was more reliably predicted by systolic as compared with diastolic BP and by pretreatment as compared to post-treatment BP, regardless of the timing and method of measurement, respectively. In particular, at the 120-minute baseline and follow-up measurements, systolic BP had no predictive value in patients with less severe renal insufficiency and baseline diastolic BP, regardless of the level of renal dysfunction. The BP predictive value was remarkably higher in ramipril than in conventionally treated patients. All follow-up—but no baseline—measurements reliably predicted the risk of ESRF in the entire study group.
In patients with progressive chronic nephropathies, systolic BP and pretreatment morning BP measurements are the most reliable predictors of disease outcome and may serve to guide antihypertensive therapy in routine clinical activities and in prospective controlled trials, particularly in patients on angiotensin-converting enzyme inhibitor therapy. Reliability and relevance of single measurements taken at different times after treatment administration are questionable.</description><subject>ACE inhibition</subject><subject>Antihypertensive agents</subject><subject>antihypertensive therapy</subject><subject>Biological and medical sciences</subject><subject>Cardiovascular system</subject><subject>diastolic blood pressure</subject><subject>end-stage renal failure</subject><subject>glomerular filtration rate</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>systolic blood pressure</subject><issn>0085-2538</issn><issn>1523-1755</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqFkE1PwzAMQCMEEmPwHyo4tzht06ZHmPiSJoEQnKM0dVmqrilJhrZ_T8qmXfElVvxsJ4-QiEJCQ9x2CWVpFtOSsSQFgAQg42myPSGzY-GUzAA4i1OW8XNy4VwXQF5lMCPvbxa9RenXOPio7o1potGicxuLkcVey7rfTTeNVt6FxHxNVW2GyLSRWlkzaBUNOIZslH6l0V2Ss1b2Dq8O55x8Pj58LJ7j5evTy-JuGas8pT6WvKUUaVvyrOFVIxmDFnJWFFnRsiqnRZlCrnKGWGdlmVelLFSIogYOBQeVzcn1fm541PcGnRed2dghrBQpBQo5pDRAfA8pa5yz2IrR6rW0O0FBTAJFJyZPYvIkJoHiT6DYhtabw3zplOxbKwel3bG_rCjNWaDu9xSGr_5otMIpjYMKwiwqLxqj_1_1CxCThrc</recordid><startdate>20001101</startdate><enddate>20001101</enddate><creator>Ruggenenti, Piero</creator><creator>Perna, Annalisa</creator><creator>Lesti, Maria</creator><creator>Pisoni, Roberto</creator><creator>Mosconi, Lidia</creator><creator>Arnoldi, Federica</creator><creator>Ciocca, Ilaria</creator><creator>Gaspari, Flavio</creator><creator>Remuzzi, Giuseppe</creator><general>Elsevier Inc</general><general>Nature Publishing</general><general>Elsevier Limited</general><scope>6I.</scope><scope>AAFTH</scope><scope>IQODW</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20001101</creationdate><title>Pretreatment blood pressure reliably predicts progression of chronic nephropathies</title><author>Ruggenenti, Piero ; Perna, Annalisa ; Lesti, Maria ; Pisoni, Roberto ; Mosconi, Lidia ; Arnoldi, Federica ; Ciocca, Ilaria ; Gaspari, Flavio ; Remuzzi, Giuseppe</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c421t-a8f11e1f783d89da550f0456636f594167204c45eeb377497a6cccc6b080680c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>ACE inhibition</topic><topic>Antihypertensive agents</topic><topic>antihypertensive therapy</topic><topic>Biological and medical sciences</topic><topic>Cardiovascular system</topic><topic>diastolic blood pressure</topic><topic>end-stage renal failure</topic><topic>glomerular filtration rate</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>systolic blood pressure</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ruggenenti, Piero</creatorcontrib><creatorcontrib>Perna, Annalisa</creatorcontrib><creatorcontrib>Lesti, Maria</creatorcontrib><creatorcontrib>Pisoni, Roberto</creatorcontrib><creatorcontrib>Mosconi, Lidia</creatorcontrib><creatorcontrib>Arnoldi, Federica</creatorcontrib><creatorcontrib>Ciocca, Ilaria</creatorcontrib><creatorcontrib>Gaspari, Flavio</creatorcontrib><creatorcontrib>Remuzzi, Giuseppe</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Pascal-Francis</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Kidney international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ruggenenti, Piero</au><au>Perna, Annalisa</au><au>Lesti, Maria</au><au>Pisoni, Roberto</au><au>Mosconi, Lidia</au><au>Arnoldi, Federica</au><au>Ciocca, Ilaria</au><au>Gaspari, Flavio</au><au>Remuzzi, Giuseppe</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pretreatment blood pressure reliably predicts progression of chronic nephropathies</atitle><jtitle>Kidney international</jtitle><date>2000-11-01</date><risdate>2000</risdate><volume>58</volume><issue>5</issue><spage>2093</spage><epage>2101</epage><pages>2093-2101</pages><issn>0085-2538</issn><eissn>1523-1755</eissn><coden>KDYIA5</coden><abstract>Pretreatment blood pressure reliably predicts progression of chronic nephropathies.
Random, nontimed blood pressure (BP) measurements in the outpatient clinic may fail to provide reliable information on actual daily BP control in renal patients on chronic antihypertensive therapy.
In a cohort of 163 patients with proteinuric chronic nephropathies followed prospectively with repeated BP and glomerular filtration rate (GFR) measurements, we compared baseline and follow-up pretreatment, morning (“trough,” measured by standard procedures, and “0 minutes,” measured by an automatic device) and post-treatment (120 minutes) measurements, with BP monitored up to 600 minutes after treatment administration. We then evaluated which BP value most reliably predicted GFR decline (δGFR) and progression to end-stage renal failure (ESRF) over a median (interquartile range) follow-up of 20 (9 to 25) months.
GFR decline was more reliably predicted by systolic as compared with diastolic BP and by pretreatment as compared to post-treatment BP, regardless of the timing and method of measurement, respectively. In particular, at the 120-minute baseline and follow-up measurements, systolic BP had no predictive value in patients with less severe renal insufficiency and baseline diastolic BP, regardless of the level of renal dysfunction. The BP predictive value was remarkably higher in ramipril than in conventionally treated patients. All follow-up—but no baseline—measurements reliably predicted the risk of ESRF in the entire study group.
In patients with progressive chronic nephropathies, systolic BP and pretreatment morning BP measurements are the most reliable predictors of disease outcome and may serve to guide antihypertensive therapy in routine clinical activities and in prospective controlled trials, particularly in patients on angiotensin-converting enzyme inhibitor therapy. Reliability and relevance of single measurements taken at different times after treatment administration are questionable.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><doi>10.1111/j.1523-1755.2000.00382.x</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0085-2538 |
ispartof | Kidney international, 2000-11, Vol.58 (5), p.2093-2101 |
issn | 0085-2538 1523-1755 |
language | eng |
recordid | cdi_proquest_journals_210104021 |
source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; ProQuest Central UK/Ireland; Alma/SFX Local Collection |
subjects | ACE inhibition Antihypertensive agents antihypertensive therapy Biological and medical sciences Cardiovascular system diastolic blood pressure end-stage renal failure glomerular filtration rate Medical sciences Pharmacology. Drug treatments systolic blood pressure |
title | Pretreatment blood pressure reliably predicts progression of chronic nephropathies |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T09%3A44%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pretreatment%20blood%20pressure%20reliably%20predicts%20progression%20of%20chronic%20nephropathies&rft.jtitle=Kidney%20international&rft.au=Ruggenenti,%20Piero&rft.date=2000-11-01&rft.volume=58&rft.issue=5&rft.spage=2093&rft.epage=2101&rft.pages=2093-2101&rft.issn=0085-2538&rft.eissn=1523-1755&rft.coden=KDYIA5&rft_id=info:doi/10.1111/j.1523-1755.2000.00382.x&rft_dat=%3Cproquest_cross%3E980035161%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=210104021&rft_id=info:pmid/&rft_els_id=S0085253815473181&rfr_iscdi=true |